Characterization of Trypanosome telomere complex
锥虫端粒复合物的表征
基本信息
- 批准号:7849189
- 负责人:
- 金额:$ 1.77万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-06-19 至 2010-09-30
- 项目状态:已结题
- 来源:
- 关键词:Africa South of the SaharaAfrican TrypanosomiasisAllelesAntigenic VariationBindingCattleCell LineCellsChromosomesCloningCo-ImmunoprecipitationsComplexGenetic TranscriptionGoalsHumanHybridsImmune systemKnock-in MouseKnock-outMass Spectrum AnalysisMembrane GlycoproteinsMonoclonal AntibodiesMutagenesisMutationParasitesPathogenesisPhenotypePlayPoint MutationProteinsRNA InterferenceRoleStructureTrypanosomaTrypanosoma brucei bruceiYeastscDNA Libraryin vivomutantnaganaoverexpressionprotein complextelomere
项目摘要
T. brucei is a parasite that causes sleeping sickness in humans and Nagana in cattle in sub-Saharan Africa.
When growing in mammalian host, T. brucei cells regularly switch their major surface glycoprotein, to evade
the host immune system - a phenomenon called antigenic variation. These surface glycoproteins are
exclusively expressed from one of ~ 20 loci located next to chromosome ends - telomeres. Telomeres in
yeasts form a specialized structure that influences transcription of genes located close by. A similar
phenomenon has also been observed in T. brucei, and telomeres may play an important role in antigenic
variation. The ultimate goal of telomere studies in Trypanosoma brucei is to understand telomere functions
in antigenic variation, an essential aspect of T. brucei pathogenesis. The fundamental step would be to
identify telomere components and characterize their functions, which is the primary goal of this proposal.
Specific Aim 1: To purify tbTRF (a double-stranded telomere DMA binding factor in T. brucei) protein
complex, using two approaches: 1) Sequential immunoprecipitate pull-down of FLAG-HA-HA tagged tbTRF
using anti-FLAG and anti-HA monoclonal antibodies. Proteins co-immunoprecipitated will be identified by
mass spectrometry. 2) Yeast 2-hybrid screen using lexA-tbTRF as bait and a T. brucei GAD-fusion cDNA
library. Candidates for tbTRF-interaction factors will be first confirmed for their interaction with tbTRF in vivo
by co-immunoprecipitation. Positive clones will be characterized for their roles in antigenic variation and
telomere functions by examination of phenotypes in knockout or RNAi knockdown cell lines.
Specific Aim 2: Select non-lethal interaction-deficient tbTRF mutations in the tbTRFH domain to better
characterize tbTRF's function. Random point mutations or small deletions will be generated in the tbTRFH
domain, using PCR cloning. Mutants that lose the interaction with wild-type tbTRF but remain the ability to
interact with themselves will be screened using both conventional and reverse 2-hybrid analysis. Cell lines
with knock-in or overexpression of these mutant alleles will be characterized for their phenotypes in
antigenic variation.
The identification of telomere complex components and subsequent characterization of their functions would
be a good starting point for studying telomere functions in antigenic variation, an essential aspect of T.
brucei pathogenesis.
布氏毛滴虫是一种寄生虫,在撒哈拉以南非洲地区引起人类昏睡病和牛的纳加纳。
当在哺乳动物宿主中生长时,布氏毛滴虫细胞会定期切换它们的主要表面糖蛋白,以逃避
宿主免疫系统--一种称为抗原变异的现象。这些表面糖蛋白是
仅由位于染色体末端附近的~20个基因座中的一个-端粒表达。端粒在
酵母菌形成一种特殊的结构,影响邻近基因的转录。一种类似的
在布氏毛滴虫中也观察到了这种现象,端粒可能在抗原性中发挥重要作用。
变种。布鲁氏锥虫端粒研究的最终目的是了解端粒的功能
在抗原变异中,布氏毛滴虫致病的一个重要方面。最基本的一步是
鉴定端粒成分并鉴定其功能,这是本提案的主要目标。
特异性目的1:纯化布氏毛滴虫双链端粒DNA结合因子tbTRF蛋白
使用两种方法:1)顺序免疫沉淀FLAG-HA-HA标记的tbTRF的下拉
使用抗FLAG和抗HA的单抗。免疫共沉淀的蛋白质将通过
质谱学。2)以LexA-tbTRF为诱饵与布氏锥虫GAD-融合基因进行酵母双杂交筛选
图书馆。TbTRF-相互作用因子的候选将首先被确认为他们在体内与tbTRF相互作用
通过免疫共沉淀法。阳性克隆的特征是它们在抗原变异和
端粒通过检测基因敲除或RNAi基因敲除细胞系的表型来发挥作用。
具体目标2:选择tbTRFH结构域中的非致命性相互作用缺陷tbTRF突变,以更好地
描述tbTRF的功能。在tbTRFH中会产生随机的点突变或小的缺失
结构域,采用PCR克隆技术。与野生型tbTRF失去相互作用但仍有能力
将使用常规和反向双杂交分析来筛选与其自身的相互作用。细胞系
随着这些突变等位基因的敲入或过度表达,将在
抗原性变异。
鉴定端粒复合体成分并随后鉴定其功能将
这是研究端粒在抗原变异中的功能的一个很好的起点,端粒是T。
布鲁斯病机。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Bibo Li其他文献
Bibo Li的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Bibo Li', 18)}}的其他基金
Mechanisms of how Trypanosoma brucei TRF maintains telomere integrity
布氏锥虫 TRF 维持端粒完整性的机制
- 批准号:
10622535 - 财政年份:2022
- 资助金额:
$ 1.77万 - 项目类别:
Telomere end processing and telomere stability maintenance in trypanosomes
锥虫的端粒末端加工和端粒稳定性维持
- 批准号:
10503111 - 财政年份:2022
- 资助金额:
$ 1.77万 - 项目类别:
Mechanisms of how Trypanosoma brucei TRF maintains telomere integrity
布氏锥虫 TRF 维持端粒完整性的机制
- 批准号:
10526882 - 财政年份:2022
- 资助金额:
$ 1.77万 - 项目类别:
Telomere end processing and telomere stability maintenance in trypanosomes
锥虫的端粒末端加工和端粒稳定性维持
- 批准号:
10677878 - 财政年份:2022
- 资助金额:
$ 1.77万 - 项目类别:
Identify 70 bp repeat-associated chromatin components by End-targeting Proteomics of Isolated Chromatin segments (PICh) and initiate their functional characterization
通过分离染色质片段 (PICh) 的末端靶向蛋白质组学鉴定 70 bp 重复相关染色质成分,并启动其功能表征
- 批准号:
10417263 - 财政年份:2021
- 资助金额:
$ 1.77万 - 项目类别:
Identify 70 bp repeat-associated chromatin components by End-targeting Proteomics of Isolated Chromatin segments (PICh) and initiate their functional characterization
通过分离染色质片段 (PICh) 的末端靶向蛋白质组学鉴定 70 bp 重复相关染色质成分,并启动其功能表征
- 批准号:
10293165 - 财政年份:2021
- 资助金额:
$ 1.77万 - 项目类别:
Characterize functions of T. brucei RAP1 and TRF in antigenic variation and telom
表征 T. brucei RAP1 和 TRF 在抗原变异和端粒中的功能
- 批准号:
8603220 - 财政年份:2007
- 资助金额:
$ 1.77万 - 项目类别:
Characterize functions of T. brucei RAP1 and TRF in antigenic variation and telom
表征 T. brucei RAP1 和 TRF 在抗原变异和端粒中的功能
- 批准号:
8107285 - 财政年份:2007
- 资助金额:
$ 1.77万 - 项目类别:
相似海外基金
The catalytic core of the proteasome as a drug target to treat Human African Trypanosomiasis
蛋白酶体的催化核心作为治疗非洲人类锥虫病的药物靶点
- 批准号:
10511408 - 财政年份:2022
- 资助金额:
$ 1.77万 - 项目类别:
A One Health approach to investigating the ecology of East African trypanosomiasis in Malawian wildlife
调查马拉维野生动物中东非锥虫病生态学的“同一个健康”方法
- 批准号:
476178 - 财政年份:2022
- 资助金额:
$ 1.77万 - 项目类别:
Studentship Programs
The catalytic core of the proteasome as a drug target to treat Human African Trypanosomiasis
蛋白酶体的催化核心作为治疗非洲人类锥虫病的药物靶点
- 批准号:
10677879 - 财政年份:2022
- 资助金额:
$ 1.77万 - 项目类别:
Multi-target approach to rational design of novel therapeutics for human African trypanosomiasis
多目标方法合理设计非洲人类锥虫病新疗法
- 批准号:
10466942 - 财政年份:2021
- 资助金额:
$ 1.77万 - 项目类别:
Multi-target approach to rational design of novel therapeutics for human African trypanosomiasis
多目标方法合理设计非洲人类锥虫病新疗法
- 批准号:
10296873 - 财政年份:2021
- 资助金额:
$ 1.77万 - 项目类别:
Multi-target approach to rational design of novel therapeutics for human African trypanosomiasis
多目标方法合理设计非洲人类锥虫病新疗法
- 批准号:
10706306 - 财政年份:2021
- 资助金额:
$ 1.77万 - 项目类别:
Reducing and replacing the animal cost of functional genetics in African trypanosomiasis
减少和替代非洲锥虫病功能遗传学的动物成本
- 批准号:
NC/W001144/1 - 财政年份:2021
- 资助金额:
$ 1.77万 - 项目类别:
Research Grant
Development of new drug for African trypanosomiasis based on elucidation of the mechanism of antiprotozoal action by ribavirin.
基于利巴韦林抗原虫作用机制的阐明,开发治疗非洲锥虫病的新药。
- 批准号:
21K18230 - 财政年份:2021
- 资助金额:
$ 1.77万 - 项目类别:
Grant-in-Aid for Challenging Research (Pioneering)
Development of a novel control measure for African trypanosomiasis based on the blocking of lifecycle progression
基于生命周期进展阻断的非洲锥虫病新型控制措施的开发
- 批准号:
20K07467 - 财政年份:2020
- 资助金额:
$ 1.77万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Drug-diagnostic co-development in Tropical Medicine, combating Human African Trypanosomiasis
热带医学药物诊断联合开发,抗击非洲人类锥虫病
- 批准号:
18KK0454 - 财政年份:2019
- 资助金额:
$ 1.77万 - 项目类别:
Fund for the Promotion of Joint International Research (Fostering Joint International Research (A))